CN116554335A - Rabbit monoclonal antibody aiming at glucose-6-phosphatase (G6 PC) and application thereof - Google Patents
Rabbit monoclonal antibody aiming at glucose-6-phosphatase (G6 PC) and application thereof Download PDFInfo
- Publication number
- CN116554335A CN116554335A CN202210597753.XA CN202210597753A CN116554335A CN 116554335 A CN116554335 A CN 116554335A CN 202210597753 A CN202210597753 A CN 202210597753A CN 116554335 A CN116554335 A CN 116554335A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- phosphatase
- rabbit monoclonal
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 57
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 title claims abstract description 14
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 title claims abstract description 14
- 101000930910 Homo sapiens Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 8
- 229920001184 polypeptide Polymers 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 6
- 230000002163 immunogen Effects 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 238000005215 recombination Methods 0.000 claims abstract description 4
- 230000002055 immunohistochemical effect Effects 0.000 claims abstract description 3
- 238000010369 molecular cloning Methods 0.000 claims abstract description 3
- 238000012216 screening Methods 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 238000001514 detection method Methods 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 7
- 238000011587 new zealand white rabbit Methods 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 abstract description 30
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000006798 recombination Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000011460 glycogen storage disease due to glucose-6-phosphatase deficiency type IA Diseases 0.000 description 3
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 3
- 238000013115 immunohistochemical detection Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 2
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 2
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 2
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 2
- 206010018464 Glycogen storage disease type I Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101100335761 Homo sapiens G6PC1 gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 230000004116 glycogenolysis Effects 0.000 description 2
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- YIGLXQRFQVWFEY-NRPADANISA-N Ala-Gln-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O YIGLXQRFQVWFEY-NRPADANISA-N 0.000 description 1
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 1
- OWSMKCJUBAPHED-JYJNAYRXSA-N Arg-Pro-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OWSMKCJUBAPHED-JYJNAYRXSA-N 0.000 description 1
- NUCUBYIUPVYGPP-XIRDDKMYSA-N Asn-Leu-Trp Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O NUCUBYIUPVYGPP-XIRDDKMYSA-N 0.000 description 1
- DATSKXOXPUAOLK-KKUMJFAQSA-N Asn-Tyr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DATSKXOXPUAOLK-KKUMJFAQSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- QJHOOKBAHRJPPX-QWRGUYRKSA-N Asp-Phe-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 QJHOOKBAHRJPPX-QWRGUYRKSA-N 0.000 description 1
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVFQOPGFOQVZTE-ACZMJKKPSA-N Cys-Gln-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O BVFQOPGFOQVZTE-ACZMJKKPSA-N 0.000 description 1
- IZUNQDRIAOLWCN-YUMQZZPRSA-N Cys-Leu-Gly Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N IZUNQDRIAOLWCN-YUMQZZPRSA-N 0.000 description 1
- KZZYVYWSXMFYEC-DCAQKATOSA-N Cys-Val-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KZZYVYWSXMFYEC-DCAQKATOSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150023900 G6PC1 gene Proteins 0.000 description 1
- FJAYYNIXQNERSO-ACZMJKKPSA-N Gln-Cys-Asp Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FJAYYNIXQNERSO-ACZMJKKPSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- HJTSRYLPAYGEEC-SIUGBPQLSA-N Glu-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)O)N HJTSRYLPAYGEEC-SIUGBPQLSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 description 1
- 102100036327 Glucose-6-phosphatase 3 Human genes 0.000 description 1
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- GNNJKUYDWFIBTK-QWRGUYRKSA-N Gly-Tyr-Asp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O GNNJKUYDWFIBTK-QWRGUYRKSA-N 0.000 description 1
- 101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 1
- 101000930907 Homo sapiens Glucose-6-phosphatase 2 Proteins 0.000 description 1
- 101000930935 Homo sapiens Glucose-6-phosphatase 3 Proteins 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- JZBVBOKASHNXAD-NAKRPEOUSA-N Ile-Val-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N JZBVBOKASHNXAD-NAKRPEOUSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 1
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- VAIWUNAAPZZGRI-IHPCNDPISA-N Ser-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N VAIWUNAAPZZGRI-IHPCNDPISA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- XXNLGZRRSKPSGF-HTUGSXCWSA-N Thr-Gln-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O XXNLGZRRSKPSGF-HTUGSXCWSA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- XVHAUVJXBFGUPC-RPTUDFQQSA-N Thr-Tyr-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XVHAUVJXBFGUPC-RPTUDFQQSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- HYVLNORXQGKONN-NUTKFTJISA-N Trp-Ala-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 HYVLNORXQGKONN-NUTKFTJISA-N 0.000 description 1
- WDIJBEWLXLQQKD-ULQDDVLXSA-N Tyr-Arg-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O WDIJBEWLXLQQKD-ULQDDVLXSA-N 0.000 description 1
- HGEHWFGAKHSIDY-SRVKXCTJSA-N Tyr-Asp-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O HGEHWFGAKHSIDY-SRVKXCTJSA-N 0.000 description 1
- SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- MYLNLEIZWHVENT-VKOGCVSHSA-N Val-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N MYLNLEIZWHVENT-VKOGCVSHSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 201000004541 glycogen storage disease I Diseases 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to the field of biotechnology, and discloses a monoclonal antibody OTIR5G10 of rabbit anti-human glucose-6-phosphatase (G6 PC), which is produced by utilizing specific B cell sorting, culture screening and molecular cloning recombination. The immunogen of the rabbit monoclonal antibody OTIR5G10 is synthesized polypeptide in the range of 80-120aa, and the amino acid sequence of an OTIR5G10 antibody light chain (VL) is shown as SEQ ID NO. 1; the amino acid sequence of the heavy chain (VH) of the otor 5G10 antibody is shown in seq id No. 2. The VL of the otor 5G10 antibody comprises 3 epitopes: CDR1, CDR2 and CDR3, the amino acid sequences of which are shown in seq id nos. 3-5, respectively, the VH region of the otor 5G10 antibody comprises 3 epitopes: CDR1, CDR2 and CDR3, the amino acid sequences of which are shown in SEQ ID No.6-8, respectively. The invention also relates to application of the anti-human glucose-6-phosphatase (G6 PC) rabbit monoclonal antibody in preparation of an immunodetection tool for detecting G6PC protein, including but not limited to an immunohistochemical kit and application in preparation of a kit for marking tumor, which provides an auxiliary means for diagnosis of diseases related to G6PC and provides a basis for preparation of a next engineering antibody.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to an anti-human glucose-6-phosphatase (G6 PC) rabbit monoclonal antibody and application thereof in immunodetection.
Background
The G6PC gene is located on chromosome 17 and encodes the liver catalytic subunit glucose-6-phosphatase. It has five exons, 12.5kb in length, encoding a 35.5kDa protein consisting of 357 amino acids. The G6PC gene is a multiple transmembrane protein expressed in the liver, kidneys and small intestine, and is involved in the last step of glycogenolysis and gluconeogenesis, and it acts in the Endoplasmic Reticulum (ER) to break down glucose-6-phosphate.
Glycogen storage disease type Ia (GSD 1 a) is a hereditary metabolic disorder caused by a deficiency of glucose-6-phosphatase (G6 Pase or G6 PC), a key enzyme in glucose homeostasis, G6Pase catalyzes the terminal reactions of hepatorenal glycogenolysis and gluconeogenesis, and hydrolysis of glucose-6-phosphate (G6P) to glucose and inorganic phosphate.
Glucose-6-phosphatase catalytic subunit (G6 PC) can catalyze the decomposition of glucose-6-phosphate into glucose and phosphate, the change of the expression level and activity of the gene directly affects the dynamic balance of glucose in organisms, the over-expression of the gene has close relation with the occurrence and development of diabetes mellitus, and the mutation of the gene can lead to glycogen storage disease type 1 a. At present, immunohistochemistry (IHC) pathology experiments are commonly used clinically to detect the expression status of proteins in cells related to diseases, however, the core of the IHC experiments is monoclonal antibodies of specific binding proteins, and the performance of the monoclonal antibodies directly determines the sensitivity and the specificity of the whole detection. Thus, finding highly specific and sensitive antibodies against G6PC is key to establishing a method for detecting G6PC in cells. Searching Chinese, U.S. patent websites, EPO, WIPO and other patent websites, using G6PC or G6PC+ monoclonal antibody or anti as keywords, and not looking up the patent related to the monoclonal antibody with high affinity and specificity combined with G6PC, and not looking up the detection of the preparation of an immunodetection kit by using the anti-G6 PC rabbit monoclonal antibody OTIR5G 10; similar documents related to the contents of the declaration of the present invention are not found in pubmed using G6PC or g6pc+ monoclonal antibody or anti as a keyword. The national drug administration website is queried and no detection reagent related to the G6PC has been registered yet.
Disclosure of Invention
The invention aims to provide an anti-G6 PC rabbit monoclonal antibody OTIR5G10 with good specificity and high affinity and application thereof in preparation of an immunodetection tool for detecting G6PC protein, which provide auxiliary diagnosis and monitoring for glycogen storage disease type Ia (GSD 1 a) and provide a foundation for preparation of a next engineering antibody.
The rabbit monoclonal antibody is rabbit monoclonal antibody OTIR5G10.
The rabbit monoclonal antibody OTIR5G10 takes synthesized G6PC polypeptide as immunogen, and is obtained by injecting New Zealand white rabbits through immunity, taking immune rabbit peripheral blood mononuclear cells (PMBCs), sorting specific B cells for culture, screening and utilizing a molecular cloning recombination technology.
The rabbit monoclonal antibody OTIR5G10 has a light chain variable region (VL) of 110aa and an amino acid sequence shown in SEQ ID NO. 1; the heavy chain (VH) of the antibody contains 109aa, and the amino acid sequence of the heavy chain (VH) is shown as SEQ ID No. 2.
The rabbit monoclonal antibody otor 5G10, wherein the VL region comprises 3 epitopes: CDR1, CDR2 and CDR3, the epitope regions are 27aa-34aa,52aa-54aa and 91aa-100aa, respectively. The amino acid sequences are shown in SEQ ID No. 3-5.
The rabbit monoclonal antibody otor 5G10, wherein the VH region comprises 3 epitopes: CDR1, CDR2 and CDR3, the epitope regions are 25aa-32aa,50aa-56aa and 94aa-98aa, respectively. The amino acid residue sequences are shown in SEQ ID No. 6-8.
The rabbit monoclonal antibody OTIR5G10 can be combined with G6PC with high specificity, and can be prepared into various immunoassay kits for detecting the G6PC by methods known to those skilled in the art. In particular, the kit is applied to an immunohistochemical kit and a tumor marking kit.
Drawings
FIG. 1 is an electrophoretogram of full-length amplification products of heavy and light chains of rabbit monoclonal antibody OTIR5G10, M is a DNA molecular weight Marker;
FIG. 2 is a diagram showing the result of Westernblot detection of rabbit monoclonal antibody OTIR5G10 specifically recognizing intact G6PC (Full length G6PC, G6 PC-FL) protein;
FIG. 3 is a graph showing the results of formalin-fixed, paraffin-embedded human liver immunohistochemistry (primary antibody, G6PC monoclonal antibody OTIR5G 10);
FIG. 4 is a graph showing the results of formalin-fixed, paraffin-embedded human kidney immunohistochemistry (primary antibody, G6PC monoclonal antibody OTIR5G 10);
FIG. 5 is a graph showing the results of formalin-fixed, paraffin-embedded human duodenal immunohistochemistry (primary antibody, G6PC monoclonal antibody OTIR5G 10).
Detailed Description
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally performed under conventional conditions, those described in the laboratory manual, or those suggested by the manufacturer.
EXAMPLE 1 preparation of G6PC rabbit monoclonal antibody
1. Preparation of G6PC immunogen
1 immunogenic polypeptide is designed according to the sequence of G6PC 1-357aa, the sequence range is 80-120aa, the purity of the polypeptide is above 90%, and the purity requirement for preparing monoclonal antibody is met. The polypeptides were synthesized by peptide biochemistry limited in a third party.
2. Immunization of animals
The synthesized G6PC polypeptide is emulsified by complete Freund's adjuvant, about 2kg of New Zealand white rabbits are immunized by subcutaneous injection, the immunization dose is 500 mug/animal, the immunization is carried out for the second time after two weeks, the incomplete Freund's adjuvant is used for emulsification, and the immunization dose is 250 mug/animal. Tail blood is taken after two times of immunization, and serum titer is measured by ELISA method gradient dilution; and judging whether to collect PBMCs or continue immunization according to the result by taking OD450 at ELISA titer 128000 as a standard and selecting rabbits with highest antibody titers for collecting the PBMCs.
3. PBMCs are separated, specific B cells are sorted, cloned and recombined, rabbits are fixed on an operating table in a supine mode, heart parts are ground, skin is disinfected by alcohol, the most obvious heart beat part is selected, 50ml of syringe is used for puncturing, blood flows into the syringe after a needle head penetrates into the heart, the needle head is quickly pulled out after required blood volume is obtained, whole blood in the syringe is transferred into a sterile 50ml tube, the whole blood is evenly mixed with equal amount of PBS and then slowly added above lymphocyte separation liquid drop by drop, centrifugation is carried out for 30 minutes at room temperature of 400 Xg, and after centrifugation, the liquid level is divided into four layers from top to bottom: the rabbit PBMCs are obtained by carefully sucking the mononuclear cell layer and washing and removing the platelet and lymphocyte separating liquid by PBS. Antigen-specific B cells were further sorted from rabbit PBMCs for culture, and the supernatant of the cultured B cells was screened for positive clones using antigen-coated ELISA plates. The positive cloned cells are collected, split, extracted to obtain RNA and reverse transcribed into cDNA, the natural paired rabbit monoclonal antibody light and heavy chain full length sequence is amplified from the cDNA of the corresponding positive clone, the rabbit monoclonal antibody expression vector is constructed by cloning recombination method, and the sequence is determined by sequencing. The results of the amplified full length PCR products are shown in FIG. 1.
4. Preparation and purification of monoclonal antibody in order to obtain rabbit monoclonal antibody recognizing human G6PC protein, the invention loads the heavy chain and light chain genes of the rabbit monoclonal antibody on an expression vector, and transfects HEK293 cells with plasmids; the culture supernatant containing recombinant rabbit monoclonal antibodies recognizing human G6PC protein was obtained from 120-144 hours of transfection. Collecting cell suspension, centrifuging to obtain supernatant, and performing antibody purification by affinity chromatography. And (3) measuring the concentration of the purified monoclonal antibody by a BCA method, and then sub-packaging and freeze-drying.
Example 2 identification of anti-G6 PC Rabbit monoclonal antibody OTIR5G10
1. Identification of rabbit monoclonal antibody OTIR5G10Westernblot
Detection was performed using Westernblot (WB). Lane 1 is cell lysate transfected with pCMV6-Entry control plasmid; lane 2 is cell lysate transfected with pCMV6-G6PC full-length expression plasmid, lane 3 is cell lysate transfected with pCMV6-G6PC2 full-length expression plasmid, lane 4 is cell lysate transfected with pCMV6-G6PC3 full-length expression plasmid, 5ug of each lysate was loaded for SDS-PAGE, and WB detection was performed after the transfection.
The results showed that the rabbit monoclonal antibody otor 5G10 specifically recognizes only the intact G6PC protein, but not the family proteins G6PC2 and G6PC3, the antibody dilution ratio: 1:5000-8000,1mg/ml, results are shown in FIG. 2.
2. Titers of rabbit monoclonal antibodies
The rabbit monoclonal antibody OTIR5G10 is diluted by a double ratio dilution method, and the antibody titer is measured by indirect ELISA, and the result shows that the rabbit monoclonal antibody OTIR5G10 related to the invention is 1.2 multiplied by 10 7 。
EXAMPLE 3 analysis of the variable region Gene and amino acid sequence of the rabbit monoclonal antibody OTIR5G10
The recombinant plasmid of the OTIR5G10 antibody is used as a DNA template, a light chain variable region and a heavy chain variable region sequencing primer are designed according to the vector sequences at the 5' ends of the light chain and the heavy chain on the template, and a sequencer ABI 3730 is adopted for sequencing. The nucleotide sequence of the variable region of the light chain and the heavy chain of the rabbit monoclonal antibody OTIR5G10 is obtained through sequencing.
And (3) respectively analyzing the nucleotide sequences of the light chain and the heavy chain by using IMGT/V-QUEST analysis software on http:// www.imgt.org through utilizing the Internet to obtain the light chain amino acid sequence of the rabbit monoclonal antibody OTIR5G10, wherein the light chain amino acid sequence is shown as SEQ ID NO.1, and the heavy chain amino acid sequence is shown as SEQ ID NO. 2. The VL has a total length of 110 amino acids, the FR has 4 domains of 26, 17, 36 and 10 amino acids, the CDR has 3 domains of 8, 3 and 10 amino acids, and the CDR1, CDR2 and CDR3 have 27aa-34aa,52aa-54aa and 91aa-100aa, respectively, and the amino acid sequences are QSVYSNNY, RAS, LGGYDCSSAD, respectively.
By analysis, the rabbit monoclonal antibody OTIR5G10VH has 109 amino acids in total length, 24, 17, 37 and 11 amino acids in the 4 domains of FR, 8, 7 and 5 amino acids in the 3 domains of CDR, 25aa-32aa,50aa-56aa and 94aa-98aa in the 3 domains of CDR, and GADLSTYG, IVSGGRP, VLGNL in the amino acid sequence.
EXAMPLE 4 immunohistochemical detection of monoclonal antibody OTIR5G10 as primary antibody
1. The experimental method comprises the following steps:
1. formalin-fixed human liver, kidney, duodenal tissues were paraffin-embedded and sectioned using a finess tissue slicer with a tissue thickness of 6 μm.
2. Dewaxing and hydration: analytical grade xylene 3X 10min, absolute ethanol 3X 10min,95% ethanol 5min, 85% ethanol 5min,75% ethanol 5min, deionized water 3min X3 times.
3. Adding antigen retrieval liquid (0.01M, pH6.0 sodium citrate buffer) into autoclave, performing autoclave for 3min, opening the autoclave when the temperature of the autoclave is reduced to about 90 ℃, taking out the specimen, and naturally cooling to room temperature. The deionized water is soaked for 3min multiplied by 3 times.
4. Tissue endogenous peroxidase was inactivated with 3% hydrogen peroxide, and left to stand at room temperature for 10min. The deionized water is soaked for 5min multiplied by 3 times.
5. Blocking solution (PBS+5% skimmed milk powder+5% normal goat serum) was added and incubated at 37℃for 60min.
6. Blocking solution was removed, no rinse was performed, G6PC mab (otor 5G 10) was added, dilution ratio: 1:2000, dilution was performed with blocking solution. Placed in a wet box and incubated at 37℃for 60min. PBST (0.1% Tween-20) was washed 2 times for 5min each. PBST (0.02% Tween-20) was washed 1 time for 5min each.
7. Polink-kit 2 (CatalogNo. D37-15) reagent 1 was added dropwise and incubated at 37℃for 10-20 minutes. The cells were washed 3 times for 5min with PBS. Polink-2 kit (Catlog No. D37-15) reagent 2 was added dropwise, incubated at 37℃for 10-20 minutes, and washed 3 times with PBS for 5min each.
8. The DAB solution (Zhonghua gold bridge ZLI-9019) is used for color development for 3 to 10 minutes. Washing with distilled water.
9. Hematoxylin counterstains the nuclei for 2min, rinsing with distilled water, and differentiating with 1% hydrochloric acid. Rinsing with distilled water for 3 times, and standing at room temperature for 1min.
10. Dehydration and transparency: 75% ethanol 5min,100% ethanol 5min 3 times, 85% ethanol 5min, 95% ethanol 5min,100% ethanol 3 x 5min; xylene 3×5min, neutral resin seals.
11. Microscopic examination, see FIGS. 3-5.
2. Experimental results:
as can be seen from the results of fig. 3-5, the antibody at lower dilution concentrations (higher dilution ratio) visible significantly specific cytoplasmic staining in human liver, kidney and duodenal tissues. The results are consistent with the localization of G6PC in cells and the specificity of tissue expression, indicating that the monoclonal antibody OTIR5G10 can be used for immunohistochemical detection of the level of G6PC protein. The OTIR5G10 immunohistochemical staining shows that the monoclonal antibody OTIR5G10 has high sensitivity and can be used for immunohistochemical detection of the expression of G6PC in normal human tissues and related tumor diseases.
Sequence listing
<110> tin-free Aodi Ruidong Biotechnology Co., ltd
<120> Rabbit monoclonal antibody against glucose-6-phosphatase (G6 PC) and use thereof
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 110
<212> PRT
<213> Oryctolagus cuniculus
<400> 1
Ala Gln Val Leu Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly
1 5 10 15
Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Val Tyr Ser Asn
20 25 30
Asn Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Gln
35 40 45
Leu Ile Tyr Arg Ala Ser Lys Leu Ala Ser Gly Val Ser Ser Arg Phe
50 55 60
Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val
65 70 75 80
Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Tyr Asp Cys
85 90 95
Ser Ser Ala Asp Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110
<210> 2
<211> 109
<212> PRT
<213> Oryctolagus cuniculus
<400> 2
Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro
1 5 10 15
Leu Thr Leu Thr Cys Thr Val Ser Gly Ala Asp Leu Ser Thr Tyr Gly
20 25 30
Val Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Ala
35 40 45
Ala Ile Val Ser Gly Gly Arg Pro Tyr Tyr Arg His Trp Ala Lys Gly
50 55 60
Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Glu Leu Lys Ile
65 70 75 80
Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Val Leu Gly
85 90 95
Asn Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
100 105
<210> 3
<211> 8
<212> PRT
<213> Oryctolagus cuniculus
<400> 3
Gln Ser Val Tyr Ser Asn Asn Tyr
1 5
<210> 4
<211> 3
<212> PRT
<213> Oryctolagus cuniculus
<400> 4
Arg Ala Ser
1
<210> 5
<211> 10
<212> PRT
<213> Oryctolagus cuniculus
<400> 5
Leu Gly Gly Tyr Asp Cys Ser Ser Ala Asp
1 5 10
<210> 6
<211> 8
<212> PRT
<213> Oryctolagus cuniculus
<400> 6
Gly Ala Asp Leu Ser Thr Tyr Gly
1 5
<210> 7
<211> 7
<212> PRT
<213> Oryctolagus cuniculus
<400> 7
Ile Val Ser Gly Gly Arg Pro
1 5
<210> 8
<211> 5
<212> PRT
<213> Oryctolagus cuniculus
<400> 8
Val Leu Gly Asn Leu
1 5
Claims (6)
1. A rabbit monoclonal antibody directed against human glucose-6-phosphatase (G6 PC), characterized in that: the rabbit monoclonal antibody is rabbit monoclonal antibody OTIR5G10.
2. The anti-human glucose-6-phosphatase (G6 PC) rabbit monoclonal antibody otor 5G10 according to claim 1, wherein: the rabbit monoclonal antibody OTIR5G10 takes synthesized polypeptide as immunogen, and is obtained by immunizing New Zealand white rabbits, taking immune rabbit peripheral blood mononuclear cells (PMBCs), sorting specific B cell culture, screening and utilizing a molecular cloning recombination technology.
3. The anti-human glucose-6-phosphatase (G6 PC) rabbit monoclonal antibody OTIR5G10 according to claim 2, wherein the light chain variable region (VL) comprises 110aa and the amino acid sequence is shown in SEQ ID NO. 1; the heavy chain (VH) of the antibody contains 109aa, and the amino acid sequence of the heavy chain (VH) is shown as SEQ ID No. 2.
4. The anti-human glucose-6-phosphatase (G6 PC) rabbit monoclonal antibody otor 5G10 according to claim 2, wherein the VL region comprises 3 epitopes: CDR1, CDR2 and CDR3, the epitope regions are 27aa-34aa,52aa-54aa and 91aa-100aa, respectively. The amino acid sequences are shown in SEQ ID No. 3-5.
5. The anti-human glucose-6-phosphatase (G6 PC) rabbit monoclonal antibody otor 5G10 according to claim 2, wherein the VH region comprises 3 epitopes: CDR1, CDR2 and CDR3, the epitope regions are 25aa-32aa,50aa-56aa and 94aa-98aa, respectively. The amino acid residue sequences are shown in SEQ ID No. 6-8.
6. The use of an anti-human glucose-6-phosphatase (G6 PC) rabbit monoclonal antibody according to claim 2, wherein the use of the anti-human glucose-6-phosphatase (G6 PC) monoclonal antibody in the preparation of a kit for the immunological detection of glucose-6-phosphatase (G6 PC) is described, including but not limited to an immunohistochemical kit and the use of the kit for the preparation of a kit for the labelling of tumors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597753.XA CN116554335A (en) | 2022-05-31 | 2022-05-31 | Rabbit monoclonal antibody aiming at glucose-6-phosphatase (G6 PC) and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597753.XA CN116554335A (en) | 2022-05-31 | 2022-05-31 | Rabbit monoclonal antibody aiming at glucose-6-phosphatase (G6 PC) and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116554335A true CN116554335A (en) | 2023-08-08 |
Family
ID=87497145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210597753.XA Pending CN116554335A (en) | 2022-05-31 | 2022-05-31 | Rabbit monoclonal antibody aiming at glucose-6-phosphatase (G6 PC) and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116554335A (en) |
-
2022
- 2022-05-31 CN CN202210597753.XA patent/CN116554335A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL9002779A (en) | VIRAL AGENT. | |
| CN101929999B (en) | Kit for detecting anti-moesin antibody | |
| US9212220B2 (en) | Methods, devices, kits and compositions for detecting roundworm | |
| Chen et al. | TgrC1 mediates cell–cell adhesion by interacting with TgrB1 via mutual IPT/TIG domains during development of Dictyostelium discoideum | |
| TW562926B (en) | Method for testing renal diseases | |
| CN113999861B (en) | Preparation method and application of polyclonal antibody of adeno-associated virus capsid protein conservation region | |
| JP2710645B2 (en) | snRNP-A antigen and fragments thereof | |
| CN114349855A (en) | Novel coronavirus Delta mutant strain specific antibody and application thereof | |
| CN106699899B (en) | Immunogen for obtaining Nrf1D protein antibody, Nrf1D protein antibody and Elisa detection kit | |
| CN109142738A (en) | Marker and its application of the ECM1 as Serologic detection liver fibrosis | |
| CN107916254B (en) | Homer1 monoclonal antibody and application thereof | |
| CN116554335A (en) | Rabbit monoclonal antibody aiming at glucose-6-phosphatase (G6 PC) and application thereof | |
| US20040170953A1 (en) | Method for detecting or assaying hbv | |
| CN109734791A (en) | People NF186 antigen, people's NF186 antibody assay kit and the preparation method and application thereof | |
| CN113214373B (en) | Neoechinococcosis antigen Murinoglobulin-2 protein | |
| CN116554332A (en) | Rabbit monoclonal antibody aiming at Prostate Stem Cell Antigen (PSCA) and application thereof | |
| JPH01501518A (en) | Assays and antibodies for N-myc protein | |
| CN112553233B (en) | Tulp2 polyclonal antibody and preparation method and application thereof | |
| CN117659187B (en) | Anti-human NUT protein rabbit monoclonal antibody and application thereof | |
| CN114990074B (en) | Hybridoma cell strain, anti-human fumarate hydratase monoclonal antibody and application thereof | |
| KR100498118B1 (en) | A mutant human hepatitis b viral strain and uses thereof | |
| CN116041471B (en) | Polyclonal antibody of truncated protein with deletion of 21 amino acids at N-terminal of anti-IFITM 3 | |
| CN109734792A (en) | People CNTN1 antigen, people's CNTN1 antibody assay kit and the preparation method and application thereof | |
| CN108982875A (en) | The preparation and application of Selenoprotein P colloidal-gold detecting-card | |
| CN110305204B (en) | Anti-human DCTN1 polyclonal antibody and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |